Resonance Health (ASX:RHT) said it will expand its TrialsWest business with a third trial site in Mandurah, Western Australia, which is expected to open in August, according to a Tuesday Australian bourse filing.
The new site is located around 60 kilometers from the nearest TrialsWest site located in the Perth suburb of Spearwood, and it will allow the firm to capitalize on its existing clinical trial workflows, including the pharmaceutical clinical trials being managed by the group.
Further new sites will be targeted in coming periods, the filing added.
Its shares rose 8% in recent trading on Tuesday.